Posted by Michael Wonder on 22 Oct 2023
US Food and Drug Administration approves BioMarin's Voxzogo (vosoritide) for children under 5 years with achondroplasia
20 October 2023 - Expanded indication in the US now includes children of all ages with achondroplasia.
BioMarin Pharmaceutical today announced that the US FDA has approved the supplemental new drug application for Voxzogo (vosoritide) to increase linear growth in paediatric patients with achondroplasia with open epiphyses.
